Medizinische Universität Graz - Research portal
Neiss Jennifer Monika |
** = Publications listed in SCI/SSCI/Pubmed
2024
Full paper/article (Journal)
** Wurm, S; Waltersdorfer, M; Loindl, S; Moritz, JM; Herzog, SA; Bachmaier, G; Berghold, A; Kashofer, K; Beham-Schmid, C; Hoefler, G; Greinix, HT; Wölfler, A; Reinisch, A; Sill, H; Zebisch, A
Acute myeloid leukemia in the next-generation sequencing era : Real-world data from an Austrian tertiary cancer care center.
Wien Klin Wochenschr. 2024;
Doi: 10.1007/s00508-024-02463-w
Web of Science
PubMed
FullText
FullText_MUG
Review
** Moritz, J; Schwab, A; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions.
Biomedicines. 2024; 12(3): 599
Doi: 10.3390/biomedicines12030599
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Pleyer, L; Klammer, P; Drost, M; Angermann, H; Keil, F; Petzer, V; Heibl, S; Moritz, J; Girschikofsky, M; Stampfl-Mattersberger, M; Pichler, A; Hartmann, BL; Aschauer, G; Schmitt, C; Vallet, S; Boros, S; Pichler, P; Hammerl-Steiner, A; Renneberg, F; Schnabel, S; Majjiga, D; Melchardt, T; Egle, A; Leisch, M; Greil, R
Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven- Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group
BLOOD. 2024; 144:
Doi: 10.1182/blood-2024-207230
Web of Science
FullText
FullText_MUG
** Pleyer, L; Vaisband, M; Klammer, P; Drost, M; Angermann, H; Keil, F; Petzer, V; Heibl, S; Moritz, J; Girschikofsky, M; Stampfl-Mattersberger, M; Pichler, A; Hartmann, BL; Aschauer, G; Schmitt, C; Vallet, S; Boros, S; Pichler, P; Hammerl-Steiner, A; Renneberg, F; Majjiga, D; Russ, G; Egle, A; Leisch, M; Melchardt, T; Zaborsky, N; Faber, V; Bewersdorf, JP; Zeidan, AM; Hasenauer, J; Greil, R
Validation of Recent Response Criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS/CMML/AML Patients Treated with HMA or HMA-Ven Using CPH Models and a CPH Deep Neural Network - Can or Should Response Criteria be Harmonized for Similarly Treated Patients?
BLOOD. 2024; 144: 7511-7513.
Doi: 10.1182/blood-2024-208073
Web of Science
FullText
FullText_MUG
2022
Full paper/article (Journal)
** Dutta, S; Moritz, J; Pregartner, G; Thallinger, GG; Brandstätter, I; Lind, K; Rezania, S; Lyssy, F; Reinisch, A; Zebisch, A; Berghold, A; Wölfler, A; Sill, H
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
Ann Hematol. 2022; 101(4):837-846
Doi: 10.1007/s00277-022-04766-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Full paper/article (Journal)
** Moritz, J; Bauernhofer, T; Mannweiler, S; Langsenlehner, T; Pummer, K; Dandachi, N; Pichler, M
Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant Prostate Cancer Patients.
In Vivo. 2020; 34(6): 3631-3638.
Doi: 10.21873/invivo.12209
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG